In this regard there are several early phase clinical trials currently recruiting for combinations of CD47:SIRPα blockers + therapeutic antibodies for solid tumors and blood cancers (Feng et al., 2019). This evidence concerns the gene CD47 and hematopoietic and lymphoid system neoplasm.